Wuhan YZY Biopharma Co (HKSE:02496) Accounts Receivable : HK$54.6 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Wuhan YZY Biopharma Co Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Wuhan YZY Biopharma Co's accounts receivables for the quarter that ended in Dec. 2024 was HK$54.6 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Wuhan YZY Biopharma Co's Days Sales Outstanding for the quarter that ended in Dec. 2024 was 86.51.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Wuhan YZY Biopharma Co's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was HK$-0.39.

Wuhan YZY Biopharma Co Accounts Receivable Historical Data

The historical data trend for Wuhan YZY Biopharma Co's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan YZY Biopharma Co Accounts Receivable Chart

Wuhan YZY Biopharma Co Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Accounts Receivable

54.57

Wuhan YZY Biopharma Co Semi-Annual Data
	Dec21	Dec22	Jun23	Dec23	Jun24	Dec24
Accounts Receivable	Get a 7-Day Free Trial			-	-	-	-	54.57

Wuhan YZY Biopharma Co Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Wuhan YZY Biopharma Co Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Wuhan YZY Biopharma Co's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	54.567	/	115.109	*	91
=	86.51

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Wuhan YZY Biopharma Co's accounts receivable are only considered to be worth 75% of book value:

Wuhan YZY Biopharma Co's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(134.82	+	0.75 * 54.567	+	0.5 * 4.548	-	253.367
-	0	-	0)	/	193.849
=	-0.39

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Wuhan YZY Biopharma Co Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Wuhan YZY Biopharma Co's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuhan YZY Biopharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan YZY Biopharma Co Ltd (HKSE:02496) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 666 Gaoxin Road, East Lake High Tech, Development Zone, Hubei Province, Wuhan, CHN

Website

https://en.yzybio.com

Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody-based therapies to treat cancer or cancer-associated complications, cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas, The Company has been operating in one reportable segment, being the discovering, developing and commercializing a new class of medicines in respect to anti-tumor bispecific antibody. It generates the majority of its revenue from PRC.

Executives

Wen Zhicheng	2201 Interest of corporation controlled by you
Guo Hong Wei
Dragon Merit Holdings Limited	2201 Interest of corporation controlled by you
Shi Yao Ji Tuan En Bi Pu Yao Ye You Xian Gong Si	2101 Beneficial owner
Cspc Pharmaceutical Group Limited	2201 Interest of corporation controlled by you
Robust Sun Holdings Limited	2201 Interest of corporation controlled by you
Wang Hongjie	2201 Interest of corporation controlled by you
He Bei Yi Er Qi Ye Guan Li Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Mei Shan Bao Shui Gang Qu Guang Rui Hong Xiang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Guo Xin Si Chuang Tou Zi Ji Jin Guan Li Bei Jing You Xian Gong Si	2201 Interest of corporation controlled by you
Nan Jing Cai Zhi Er Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Cdh 2018 Vgc Investment Fund, L.p.	2201 Interest of corporation controlled by you
Nan Ning Hui You Xing Yao Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo
Nan Ning Yao You Shang Wu Zi Xun He Huo Qi Ye You Xian He Huo
Wen Zhi Cheng

Wuhan YZY Biopharma Co Headlines

No Headlines